PT - JOURNAL ARTICLE AU - Gerda C. Leitner AU - Gerhard Hagn AU - Laura Niederstätter AU - Andrea Bileck AU - Kerstin Plessl-Walder AU - Michaela Horvath AU - Vera Kolovratova AU - Andreas Tanzmann AU - Alexander Tolios AU - Werner Rabitsch AU - Philipp Wohlfarth AU - Christopher Gerner TI - INTERCEPT pathogen reduction of platelet concentrates induces trans-arachidonic acids and affects eicosanoid formation AID - 10.1101/2022.04.06.22273484 DP - 2022 Jan 01 TA - medRxiv PG - 2022.04.06.22273484 4099 - http://medrxiv.org/content/early/2022/04/07/2022.04.06.22273484.short 4100 - http://medrxiv.org/content/early/2022/04/07/2022.04.06.22273484.full AB - Gamma-irradiation of blood products is mandatory to avoid graft versus host disease in patients with immunosuppressed clinical conditions. Pathogen inactivation techniques were implemented to optimize safe blood component supply. The INTERCEPT treatment uses amotosalen together with UVA irradiation. The functional and molecular implications of these essential treatments have not yet been systematically assessed. The irradiation-induced inactivation of nucleic acids may actually be accompanied with modifications of chemically reactive polyunsaturated fatty acids, known to be important mediators of platelet functions. Thus, here we investigated eicosanoids and related fatty acids released upon treatment and during platelet storage for 7 days, complemented by the analysis of functional and metabolic consequences of these treatments. In contrast to gamma-irradiation, here we demonstrate that UVA treatment attenuated the formation of ALOX12-products such as 12-HETE and 12-HEPE but induced the formation of trans-arachidonic acids in addition to 11-HETE and HpODEs. Metabolic and functional issues like glucose consumption, lactate formation, platelet aggregation and clot firmness hardly differed between the two treatment groups. In vitro synthesis of trans-arachidonic acids (trans-AA) out of arachidonic acid in the presence of β-mercaptoethanol suggested that thiol radicals formed by UVA treatment are responsible for the INTERCEPT-specific effects observed in platelet concentrates. It is plausible to assume that trans-AA and other UVA-induced molecules may have specific biological effects on the recipients, which need to be addressed in future studies.Key pointsA previously unrecognized radical mechanisms for the generation of trans-fatty acids by UVA was identifiedIrradiation with UVA was found to immediately affect the generation of polyunsaturated fatty acid oxidation productsCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethics Committee of the Medical University of Vienna. All donors gave written informed consent to participate in this study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsAAarachidonic acidCADcompound adsorption deviceCFTclot formation timeEtOHethanolFAformic acidHETEshydroxyeicosatetraenoic acidsHPLChigh-performance liquid chromatographyHpODEshydroperoxyoctadecadienoic acidsLDHlactatdehydrogenaseLTAlight transmission aggregometryMAmaximal aggregationMCFmaximal clot firmnessMeOHmethanolMSmass spectrometryPCsplatelet concentratesPIpathogen inactivationPltplateletPRpathogen reductionrWBCresidual white blood cellsSDstandard deviationSPEsolid-phase extractionTA-GvHDtransfusion associated graft versus host diseaseTEMthromboelastometryTRAP-6thrombin receptor agonist peptide-6TTIstransfusion transmitted infectionsyIRRgamma irradiation